



New Generic Medications to Hit the Market in 2014

The pharmaceutical industry will experience some fairly substantial changes in 2014 as several high cost medications will come off patent and become available on a generic basis. The emergence of these changes bodes well for employers and plan sponsors who should benefit from cost reductions to their group pharmacy plans. The transfer of such medications is commonplace in the industry, but the 2014 class of drugs includes some meaningful medications. Below is the list of 2014 medications that will be available on a generic basis in the near term:

Brand Name (Generic)	Manufacturer	Therapeutic Use(s)	Estimated U.S. Sales *	Anticipated Generic Availability
Vanos (fluocinonide cream)	Medicis	Dermatoses	\$98.6 million	December 2013
Vivelle-Dot (estradiol transdermal patch)	Novartis	Treating Symptoms Associated with Menopause	\$240 million	December 2013
Diovan (valsartan hydrochloride)	Novartis	Hypertension; Heart Failure; Reduction of Cardiovascular Mortality after Myocardial Infarction	\$2.1 billion	Q1 2014
Valcyte (valganciclovir)	Roche	Cytomegalovirus (CMV) Disease and Infection; CMV Retinitis	\$195 million	Q1 2014
Advicor (niacin/lovastatin)	AbbVie	Hyperlipidemia	\$42 million	Q1 2014
Xeloda (capecitabine)	Roche	Breast Cancer; Colorectal Cancer	\$300 million	Q1 2014
Detrol LA (tolterodine tartrate extended-release)	Pfizer	Overactive Bladder	\$599 million	Q1 2014
Asacol (mesalamine)	Warner Chilcott	Ulcerative Colitis	\$460 million	January 2014
Loestrin 24 FE (ethinyl estradiol/norethindrone acetate)	Warner Chilcott	Prevention of Pregnancy	\$396 million	January 2014
Micardis (telmisartan)	Boehringer Ingelheim	Hypertension; Cardiovascular Risk Reduction	\$249 million	January 2014
Micardis HCT (telmisartan/hydrochlorothiazide)	Boehringer Ingelheim	Hypertension	\$218 million	January 2014
Rapamune Oral Tab (sirolimus)	Wyeth/Pfizer	Prevention of Organ Transplant Rejection	\$231 million	January 2014
Avelox (moxifloxacin)	Schering/Merck	Bacteria Infections	\$376 million	February 2014
Hectorol (doxercalciferol)	Genzyme	Hyperparathyroidism	\$41 million	February 2014
Evista (raloxifene)	Eli Lilly	Osteoporosis; Reduction in Risk of Invasive Breast Cancer	\$700 million	March 2014
Renvela (sevelamer carbonate)	Genzyme	Hyperphosphatemia Associated with Chronic Kidney Disease	\$200 million	March 2014

Should you have any questions about generic medications or your pharmacy plan, please contact your Conner Strong & Buckelew representative.



connerstrong.com



877-861-3220



news@connerstrong.com



[Change My Preferences](#)

CONNER
STRONG &
BUCKLEW

INSURANCE | RISK MANAGEMENT | EMPLOYEE BENEFITS



[Click here to change your email preferences or unsubscribe from all communication.](#)